ONA Therapeutics Selects Lead Drug Candidate

Barcelona-based ONA Therapeutics has selected a lead therapeutic candidate, beginning pharmacology and toxicology studies. 

The company was founded as a spin off from the Institute of Research in Biomedicine and the Catalan Institution for Research and Advanced Studies in 2019. Since then, the company has been a contender for The Spinoff Prize 2021 and longlisted for The Spinoff Prize 2023.

ONA Therapeutics was founded to advance an antibody-drg strategy that could blunt the spread of cancer and reduce the burden of metastasis. This was based on research in a lab, where the antibody-drug strategy showed promising results in mice subjects. Following this effort, the company raised €30 million in venture capital funding and spun off into their own dedicated laboratory space.

The selection of a lead candidate has also encouraged the company to begin striving towards clinical trials in the next few years.

Research has required detailing how the therapeutic approach works at a molecular level. They also made a humanised antibody to create the drug candidate ONA-046, which holds promise for treating deadly forms of advanced cancer.

Their lead candidate, ONA-046, is directed against a fatty-acid receptor found on the surface of many cells, including those that drive metastasis. On those cells, the receptor acts as a gullet for fat intake, helping to feed the voracious appetite of cancers in ways that fuel their invasiveness and migration. By cutting off this source of fat, the antibody triggers a metabolic rewiring which proves lethal to cancer-propagating cells.

Additional research has shown that the candidate might make drug-resistant cells vulnerable to various ani-cancer agents. This means, treatment with this antibody may help to shrink tumours on two fronts – by directly affecting metastasis-initiating cells and by indirectly enhancing anti-cancer immune surveillance mechanisms.

Who We Are:

Research and development is the engine of economic growth in an increasingly knowledge-based global economy, however more investment is needed to help boost human creativity, innovation and economic output. 

Swanson Reed is one of Spain’s largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

To find out more about R&D or to determine the eligibility of your business for receiving an R&D tax credit, contact a Swanson Reed R&D Tax Advisor today.

Recent Posts

Leave a Comment